Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NIPheItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMEC2Olkh|ryP NIK5fIdUSU6JRWK=
MV-4-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknyTWM2OD1yLkCxOVg3KM7:TR?= NWnzV4c4W0GQR1XS
NKM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjXTWM2OD1yLkCxOlk6KM7:TR?= MWDTRW5ITVJ?
ML-2 M4jmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\lNmlEPTB;MD6wNVk5OyEQvF2= MYTTRW5ITVJ?
BV-173 NHjScWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;CT3pTUUN3ME2wMlAzOzF2IN88US=> M3;CTXNCVkeHUh?=
RS4-11 M{fyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTNTWM2OD1yLkCyOVg4KM7:TR?= NUj5eox2W0GQR1XS
HL-60 NHXGRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLQNYdkUUN3ME2wMlAzQTB6IN88US=> M3\NNXNCVkeHUh?=
KY821 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OxZmlEPTB;MD6wNlk4PSEQvF2= NG\jOnZUSU6JRWK=
ECC10 NWPLXYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hzc2lEPTB;MD6wN|c6OiEQvF2= MoLjV2FPT0WU
NCI-H720 M4PVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMESwNVEh|ryP MkS5V2FPT0WU
QIMR-WIL MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHodmtKSzVyPUCuNFQzQDdizszN NIDpOlJUSU6JRWK=
KG-1 NH7HbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMES0PFYh|ryP NV7Uc4ZvW0GQR1XS
TGW M4q0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD1yLkC0OlM{KM7:TR?= NELqfINUSU6JRWK=
ATN-1 MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OxcGlEPTB;MD6wOFc{OyEQvF2= MWfTRW5ITVJ?
RH-18 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDYb3lKSzVyPUCuNFYxPDhizszN NH36NVJUSU6JRWK=
EW-18 NHnQZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1WnVrUUN3ME2wMlA3QDRzIN88US=> M{DXZnNCVkeHUh?=
NB17 M33he2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LsVGlEPTB;MD6wO|EzPCEQvF2= NILkOGRUSU6JRWK=
SK-NEP-1 NUntXGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\vTWM2OD1yLkC3NlE{KM7:TR?= Mlf2V2FPT0WU
P12-ICHIKAWA NYLsfoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEe3O|gh|ryP NGLZeI9USU6JRWK=
KARPAS-45 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEe4NVUh|ryP M3rHVHNCVkeHUh?=
EW-3 M3HXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljJTWM2OD1yLkC4NFU{KM7:TR?= NF;kWG5USU6JRWK=
NB13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTsTWM2OD1yLkC4NlA{KM7:TR?= NYHKfFVmW0GQR1XS
NCI-H209 M4TWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HEbWlEPTB;MD6wPFcxPCEQvF2= NH\Lc3NUSU6JRWK=
NCI-H1092 M3fINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMUCyO|Uh|ryP MXrTRW5ITVJ?
NH-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T0UGlEPTB;MD6xNFc1PCEQvF2= NHfoWGVUSU6JRWK=
697 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q2PGlEPTB;MD6xNFg{QSEQvF2= MXLTRW5ITVJ?
KE-37 M1LISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMUGzO{DPxE1? MknEV2FPT0WU
MOLT-4 M133WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVyzO4VmUUN3ME2wMlE2OTZ7IN88US=> MVjTRW5ITVJ?
CHP-134 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInDSm5KSzVyPUCuNVY{ODZizszN NUWybHVrW0GQR1XS
D-283MED MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vuVmlEPTB;MD6xO|Y5PiEQvF2= NUTEVGhkW0GQR1XS
LU-135 NG\w[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMUi1OVIh|ryP Mn\GV2FPT0WU
LU-134-A NWHmZ2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz0SY9WUUN3ME2wMlE5PjdzIN88US=> M3Ty[3NCVkeHUh?=
EM-2 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TnV2lEPTB;MD6xPVkyQCEQvF2= MnS1V2FPT0WU
LU-139 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnxS5pKSzVyPUCuNlA1QThizszN NGT4Z29USU6JRWK=
ALL-PO MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy5fZpkUUN3ME2wMlIyQTh6IN88US=> M2rOc3NCVkeHUh?=
NB12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW2TWM2OD1yLkKzNVE2KM7:TR?= MXTTRW5ITVJ?
KP-N-YN M1HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G0dGlEPTB;MD6yN|U4OyEQvF2= MVzTRW5ITVJ?
BEN MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHmbY9LUUN3ME2wMlI{QTZ6IN88US=> NYDvcZRjW0GQR1XS
HCC1569 M3vrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[yWoNKSzVyPUCuNlUyODZizszN MorrV2FPT0WU
HuO9 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Pl[GlEPTB;MD6yOlcyPSEQvF2= NXXUXo9pW0GQR1XS
WM-115 M13td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfBXlZKSzVyPUCuNlc4OzhizszN MkPSV2FPT0WU
CCRF-CEM NGX5dYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwM{O1Nlkh|ryP NXXXbIk3W0GQR1XS
IST-SL1 M1X1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\uOGFoUUN3ME2wMlM2OzR|IN88US=> MUDTRW5ITVJ?
BE-13 NWf5So84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTo[XdHUUN3ME2wMlM3PDV7IN88US=> MnnmV2FPT0WU
COR-L88 NITZfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwM{[1OEDPxE1? NH35e|BUSU6JRWK=
DOHH-2 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHnOpNyUUN3ME2wMlQyODJ|IN88US=> MWHTRW5ITVJ?
A704 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwNEK2O{DPxE1? NFv2epRUSU6JRWK=
KNS-81-FD NF24SnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHiTWM2OD1yLkS0NFE4KM7:TR?= Mn\sV2FPT0WU
RPMI-8226 NXL3bHF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nGV2lEPTB;MD60OVY2OiEQvF2= NEPaPHdUSU6JRWK=
TGBC24TKB NHvQWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm5TWM2OD1yLkS1O|c5KM7:TR?= Moq1V2FPT0WU
NCI-H1304 NWXlW2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\j[GlEPTB;MD60OlE2PyEQvF2= MXzTRW5ITVJ?
MOLT-13 NHPkc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rPVWlEPTB;MD60OlYyOyEQvF2= M{m0U3NCVkeHUh?=
EW-22 M{Tncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi4Z|FZUUN3ME2wMlQ3PjdzIN88US=> MoDEV2FPT0WU
MS-1 M{LQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TMT2lEPTB;MD60Olk{OyEQvF2= NHv5SIZUSU6JRWK=
RMG-I M2XtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfGPHhKSzVyPUCuOFk1PjRizszN NFSw[3ZUSU6JRWK=
NTERA-S-cl-D1 NVrxUXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTtT2tKSzVyPUCuOVAxOTlizszN MX3TRW5ITVJ?
NCI-H1048 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr1cW1KSzVyPUCuOVA6PTNizszN NVP4U2pnW0GQR1XS
SW1417 M3y0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjIdZpwUUN3ME2wMlU2PDN6IN88US=> Mn\WV2FPT0WU
DB M3:ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwNUewPEDPxE1? Mm\4V2FPT0WU
MEG-01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLXN2NXUUN3ME2wMlU5OzJizszN M4TiXnNCVkeHUh?=
EW-13 M2D1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13mWmlEPTB;MD61PFM1OSEQvF2= MY\TRW5ITVJ?
LAMA-84 NF60ZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPyOoRKSzVyPUCuOVkzODdizszN NFzrb4pUSU6JRWK=
J-RT3-T3-5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwTmlEPTB;MD62NFgxQCEQvF2= M3;2V3NCVkeHUh?=
MOLT-16 M3frPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwNkWyOlQh|ryP NX:zTI9EW0GQR1XS
DU-4475 NFTvVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNkW0Nlch|ryP MWfTRW5ITVJ?
HAL-01 NWrLbXB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfSRYNQUUN3ME2wMlczPTR7IN88US=> Mkj5V2FPT0WU
RD MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwN{W4PVkh|ryP NW\5XJdMW0GQR1XS
OAW-28 NUjub2lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknWTWM2OD1yLke4N|ch|ryP MYTTRW5ITVJ?
HCC38 NVvCdIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwOECxPUDPxE1? MXfTRW5ITVJ?
NMC-G1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\vd2dKSzVyPUCuPFEyOjFizszN Mn;rV2FPT0WU
EW-16 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:xOGlEPTB;MD64NVMzQCEQvF2= M1\QfXNCVkeHUh?=
DU-145 NUfafY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXXWHRzUUN3ME2wMlg6QTJ|IN88US=> M33DbnNCVkeHUh?=
HPAF-II MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfITWM2OD1yLkmyOlI5KM7:TR?= MUTTRW5ITVJ?
A427 NH7XZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\1cmlEPTB;MD65N|AzOiEQvF2= MoTEV2FPT0WU
PA-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\sRWlEPTB;MD65OVY1OiEQvF2= M1PNPXNCVkeHUh?=
OAW-42 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKwTWM2OD1yLkm2NVQ3KM7:TR?= NWj2eGVzW0GQR1XS
L-428 M{XoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXSbo9KSzVyPUGuNFEzPSEQvF2= MXjTRW5ITVJ?
COLO-824 NYjVT|h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXRc|lKSzVyPUGuNFE4ODhizszN MX7TRW5ITVJ?
P30-OHK NXn2eXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn6UWtKSzVyPUGuNFQ3QDhizszN NHztbFhUSU6JRWK=
NCI-H2170 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPDTWM2OD1zLkC2NlMh|ryP NVLhZW5LW0GQR1XS
HCC2998 NVzjb|VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Hzc2lEPTB;MT6wO|E{PSEQvF2= MVjTRW5ITVJ?
NB14 NUfv[FlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHWxVmhKSzVyPUGuNVM4PDhizszN M2\zS3NCVkeHUh?=
TGBC1TKB M1PyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMUSxOVIh|ryP MYDTRW5ITVJ?
KP-N-YS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\vXohGUUN3ME2xMlE3OjN4IN88US=> NV3KbFZjW0GQR1XS
CAL-120 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrMcJRKSzVyPUGuNVY1OjlizszN MXLTRW5ITVJ?
SBC-1 NUjsOFA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELpNlVKSzVyPUGuNVkxPTNizszN NXjvU|RsW0GQR1XS
C32 NXe1fYZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ZUpI2UUN3ME2xMlE6ODh6IN88US=> MV;TRW5ITVJ?
HCC2157 NEe4VIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PZOmlEPTB;MT6xPVQ6PCEQvF2= MnrkV2FPT0WU
COLO-792 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwMkCwO|Eh|ryP MUTTRW5ITVJ?
ES7 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jRTGlEPTB;MT6yO|k2OSEQvF2= M3v6T3NCVkeHUh?=
HEL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\2XJNxUUN3ME2xMlMyODJ7IN88US=> NU\KSIZHW0GQR1XS
ES4 NFHlW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwM{S5PVgh|ryP NYTBcooyW0GQR1XS
NCI-SNU-1 NY\YcI86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwM{[1OVUh|ryP NVXkVIxWW0GQR1XS
MDA-MB-415 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT0TWM2OD1zLkO4PFUh|ryP NVLDbohWW0GQR1XS
NCI-H2342 NFP0bFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTvN5FQUUN3ME2xMlQxOjZ7IN88US=> MlTHV2FPT0WU
NB69 NF7TNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojWTWM2OD1zLkS2NlcyKM7:TR?= Ml2wV2FPT0WU
D-247MG NHuwOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHaTWM2OD1zLkWxNVIzKM7:TR?= NXrXV4ZlW0GQR1XS
SCC-4 M4S4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjRTWM2OD1zLkW5PFg4KM7:TR?= NUD0OFNEW0GQR1XS
HuH-7 M4K1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVToTlRVUUN3ME2xMlY4Ojl|IN88US=> NHH2bGhUSU6JRWK=
A388 NVvudJhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD0TWM2OD1zLk[4O|I1KM7:TR?= MmSyV2FPT0WU
Calu-3 NHvKemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6[GlEPTB;MT63NFY6PyEQvF2= MlLLV2FPT0WU
NCI-H1648 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwN{G0NVgh|ryP NFXvToRUSU6JRWK=
NCI-H2052 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLYTWM2OD1zLkeyNlAyKM7:TR?= MU\TRW5ITVJ?
Ramos-2G6-4C10 NXz0Z|BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjXTWM2OD1zLkezOlU3KM7:TR?= Mn;GV2FPT0WU
DEL M2mxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzCOINKSzVyPUGuO|Q3QTJizszN MlvsV2FPT0WU
SNU-423 NWrQSHhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn3flFuUUN3ME2xMlc5OTV5IN88US=> Mlf1V2FPT0WU
COR-L23 NVTid4xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXwR4l{UUN3ME2xMlc6QDd2IN88US=> MWfTRW5ITVJ?
OMC-1 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\zTWM2OD1zLki2NFE3KM7:TR?= NHvBeXBUSU6JRWK=
EW-11 NGjRTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX0dWRuUUN3ME2xMlk2PjV5IN88US=> MVTTRW5ITVJ?
HSC-3 NF7zZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwOU[zOlUh|ryP MoHkV2FPT0WU
MLMA NIriS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXofGxKSzVyPUGuPVY3PzdizszN MWfTRW5ITVJ?
RCM-1 M37T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HzNWlEPTB;Mj6wNFM6QSEQvF2= NX3wd4N3W0GQR1XS
MFE-280 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwMEK4OFgh|ryP NUTnbodIW0GQR1XS
ES8 M3HGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwMkW0O|Eh|ryP M4\3[nNCVkeHUh?=
TE-11 NUK3[oxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PBZ2lEPTB;Mj6yPVQ4OyEQvF2= M4LBOnNCVkeHUh?=
HuO-3N1 NFjJ[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXZN|hIUUN3ME2yMlQ5PzhizszN NHruVJNUSU6JRWK=
MHH-NB-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDsUXVKSzVyPUKuOVEyPThizszN MWjTRW5ITVJ?
TGBC11TKB M3W4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDxUHJwUUN3ME2yMlU4PjhzIN88US=> M3zMOXNCVkeHUh?=
HOP-92 M37vUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\yTWM2OD1{LkW4O|Q{KM7:TR?= M4HUS3NCVkeHUh?=
IGR-1 M1K1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnTTWM2OD1{Lk[yNFM2KM7:TR?= MkniV2FPT0WU
GOTO NHz4bYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwNkWzO|ch|ryP NHi0dotUSU6JRWK=
NCI-H1650 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL3epVlUUN3ME2yMlczOjF3IN88US=> NIn4[2NUSU6JRWK=
NCI-H1581 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\Xd2lEPTB;Mj63PVY5OSEQvF2= M3;ZRnNCVkeHUh?=
NCI-H2405 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fMUWlEPTB;Mj64Nlc5OiEQvF2= MnS3V2FPT0WU
U-118-MG MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJwOU[0PVEh|ryP MV\TRW5ITVJ?
DoTc2-4510 NHjvTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[2WpBOUUN3ME2zMlAyPDF5IN88US=> NY\WZmhMW0GQR1XS
NCI-H596 NWPHO5VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DaXmlEPTB;Mz6wOFk6PyEQvF2= NVz3XVZqW0GQR1XS
MPP-89 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v4RmlEPTB;Mz6wOVY3PiEQvF2= M2XW[HNCVkeHUh?=
GCIY M3fpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNwMkC0PVEh|ryP MlHaV2FPT0WU
SW626 NVX2N2VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zYUGlEPTB;Mz6yOFU1OyEQvF2= M{K1b3NCVkeHUh?=
OCI-AML2 NF\GeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH6TWM2OD1|LkOxNlczKM7:TR?= MX3TRW5ITVJ?
NBsusSR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNwM{S5N|gh|ryP MnvTV2FPT0WU
AN3-CA M2f1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnFTodKSzVyPUOuOFQzOzhizszN MVPTRW5ITVJ?
EFM-19 M1jDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TwbWlEPTB;Mz60PFM{QSEQvF2= MX\TRW5ITVJ?
RVH-421 M4S1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nVTWlEPTB;Mz61Olg4PyEQvF2= Mn;RV2FPT0WU
5637 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTNwNkGxNFMh|ryP NEf2Z4VUSU6JRWK=
PANC-08-13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwNkO0O|Ih|ryP MWTTRW5ITVJ?
H9 NYWyeY56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvlfZlKSzVyPUOuOlcyPDRizszN MmTNV2FPT0WU
KARPAS-299 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHTTWM2OD1|Lk[3N|YyKM7:TR?= NYftXmxLW0GQR1XS
TE-5 MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNwN{C3NFkh|ryP M{PWU3NCVkeHUh?=
NOS-1 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzG[odDUUN3ME2zMlc6QDN2IN88US=> NGn2SmFUSU6JRWK=
HH M{P1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TzXGlEPTB;Mz64N|g3QCEQvF2= MVzTRW5ITVJ?
769-P MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nQeWlEPTB;Mz64PVUyKM7:TR?= MmfwV2FPT0WU
CHP-212 NUnDT3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzlN3ZKSzVyPUOuPVI2PDlizszN MoP5V2FPT0WU
NCI-H82 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\vW|hKSzVyPUOuPVU6OzZizszN NFTjOlBUSU6JRWK=
Mo-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTGTWM2OD12LkC0N|EzKM7:TR?= M{PFTXNCVkeHUh?=
BB65-RCC MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7MTpJsUUN3ME20MlA1Ozl7IN88US=> NGnzdI5USU6JRWK=
SW1990 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLkTnVZUUN3ME20MlA2QTB6IN88US=> MWHTRW5ITVJ?
LK-2 NIH0b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRwMUGyPVMh|ryP M13TW3NCVkeHUh?=
ES5 NGq2[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPaNW5ZUUN3ME20MlE{QTh3IN88US=> MniyV2FPT0WU
JVM-3 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm5dHB7UUN3ME20MlE5OjJ{IN88US=> MnfVV2FPT0WU
RPMI-7951 NGLuUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi5U5pPUUN3ME20MlIzPDF|IN88US=> MVjTRW5ITVJ?
Calu-6 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfUdZRHUUN3ME20MlI4QDhzIN88US=> M1z0XHNCVkeHUh?=
LC-2-ad NGLIOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHwVoQ1UUN3ME20MlI6PTZ6IN88US=> M1jzWXNCVkeHUh?=
SW954 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwMkm2OkDPxE1? MlnhV2FPT0WU
H-EMC-SS NWLiXIQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfhZWVlUUN3ME20MlMyQDNzIN88US=> NXrETHVuW0GQR1XS
ES3 M4T0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwM{W0OFEh|ryP M{nvd3NCVkeHUh?=
no-11 NV20UpdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vjSWlEPTB;ND6zOVU2PCEQvF2= M3fPOnNCVkeHUh?=
LAN-6 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwNEWxPFkh|ryP MoLWV2FPT0WU
FTC-133 NHjYW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLETWM2OD12LkWzPVUh|ryP MY\TRW5ITVJ?
8505C NEfnXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRwNUSyN{DPxE1? MWHTRW5ITVJ?
SW620 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXJTWM2OD12LkW3NFU4KM7:TR?= MV\TRW5ITVJ?
BCPAP NHTkdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rvOGlEPTB;ND62N|Q5OSEQvF2= MV\TRW5ITVJ?
SK-LU-1 M1T3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjQVnBKSzVyPUSuOlYxQDlizszN MVzTRW5ITVJ?
NCI-H1623 M{T1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLsbo1UUUN3ME20MlcxOjJ6IN88US=> NVPhPIFpW0GQR1XS
C2BBe1 M2nBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Ky[mlEPTB;ND63OFAxQCEQvF2= M2Xk[nNCVkeHUh?=
GP5d M1zrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfCTWM2OD12Lke4N|g5KM7:TR?= M1qxenNCVkeHUh?=
NB6 NGTteG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRwOE[yNFQh|ryP NFqyS2VUSU6JRWK=
MDA-MB-157 NUDZOY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPTTXJ4UUN3ME20Mlg5PzZizszN M{nqbXNCVkeHUh?=
UMC-11 M{nMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwOEi5OlQh|ryP Mn;qV2FPT0WU
HCC1419 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTRwOUCwOlMh|ryP M{\2dHNCVkeHUh?=
NCI-H2029 NUfRbXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnXV2V6UUN3ME20Mlk1OTh3IN88US=> M2DsR3NCVkeHUh?=
LXF-289 M{D3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTVwMEO3NVkh|ryP NUPzfGZLW0GQR1XS
KINGS-1 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\xd2FKSzVyPUWuNFc4PDRizszN NGDLWmFUSU6JRWK=
HD-MY-Z NWnnfFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDN[Jc1UUN3ME21MlI{QTZ7IN88US=> M4\LXHNCVkeHUh?=
ESS-1 NY\2[5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;BTpBKSzVyPUWuNlU2QTdizszN MofrV2FPT0WU
GI-1 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;WUnFKSzVyPUWuNlc6OjZizszN NWL2UWo4W0GQR1XS
RPMI-2650 NXzpOVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS0bZZXUUN3ME21MlM3OTZizszN MlPoV2FPT0WU
IA-LM MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\OTWM2OD13LkO5PFcyKM7:TR?= MVTTRW5ITVJ?
KP-4 NVr3PG9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtTWM2OD13LkS2N|M1KM7:TR?= MV3TRW5ITVJ?
G-402 M{fmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzWNWFKSzVyPUWuOVE5PjVizszN MYrTRW5ITVJ?
OS-RC-2 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTVwNUK2NFQh|ryP NEDBRYFUSU6JRWK=
NCI-H1155 NYD6d5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC3b|lQUUN3ME21MlU1QTV3IN88US=> NHv4TVNUSU6JRWK=
OE19 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTVwNki2NlQh|ryP Mn\TV2FPT0WU
U-2-OS Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTVwOEmwNVMh|ryP M1u3OXNCVkeHUh?=
SCC-15 NFG1NoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP6bWpTUUN3ME21Mlk{PjZ{IN88US=> MnnVV2FPT0WU
NCI-H630 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTVwOUm0NFQh|ryP NE\xTmVUSU6JRWK=
PFSK-1 M3LCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjJR3FpUUN3ME22MlA2OjV7IN88US=> NWXUcYU4W0GQR1XS
NCI-H1770 NVv6ZoRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZwMkC4O|Qh|ryP NEjYUIVUSU6JRWK=
SK-MEL-3 M{XE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rwcWlEPTB;Nj60NlkyPSEQvF2= MXjTRW5ITVJ?
LB1047-RCC NF3rUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTzW4lKSzVyPU[uOFc3OjVizszN Mn7QV2FPT0WU
NCI-H446 NU\3NFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH3dYJKSzVyPU[uOlI6OjVizszN M4jkRnNCVkeHUh?=
SW780 NWjuWWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTZwN{CxPFUh|ryP M3zwW3NCVkeHUh?=
NEC8 NV;Dd2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XNeGlEPTB;Nj63OlY{KM7:TR?= Mlr4V2FPT0WU
NOMO-1 M1LQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrqSGc4UUN3ME22Mlc5OTFzIN88US=> MYfTRW5ITVJ?
COLO-668 NIXQW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPX[JR{UUN3ME22Mlg1Ozh5IN88US=> Moi0V2FPT0WU
MC116 NIWzXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PvemlEPTB;Nj65N|g6PyEQvF2= MWDTRW5ITVJ?
HCC1937 NUPSVWxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK5SFBoUUN3ME22Mlk6OjVzIN88US=> M{fCTnNCVkeHUh?=
NCI-N87 NHXmXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3eWlEPTB;Nz6xPVI6OyEQvF2= NYjGVXBnW0GQR1XS
COLO-320-HSR NEf0XGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTdwMkK3N|gh|ryP M{P0WXNCVkeHUh?=
HCC1806 NWOzdVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[1R2cxUUN3ME23MlI3ODR2IN88US=> NWS0UYRSW0GQR1XS
OVCAR-3 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTdwM{OwN|gh|ryP M1zaeHNCVkeHUh?=
NUGC-3 NWT0RmZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTdwM{m2PVQh|ryP MYjTRW5ITVJ?
SW1783 NID4cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTdwNEOxO|Uh|ryP M{OxZ3NCVkeHUh?=
GCT M4Tyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTdwNU[5NFYh|ryP M3rxUHNCVkeHUh?=
NCI-H2126 M4ruUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTdwN{O2NlUh|ryP MWTTRW5ITVJ?
MEL-HO M1;pNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfoNJNIUUN3ME23Mlc4ODV2IN88US=> M3Ls[HNCVkeHUh?=
CAPAN-1 NH;rW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\vbHFiUUN3ME23Mlc4OzV5IN88US=> M{fwbHNCVkeHUh?=
SW756 NVHJeGs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XifGlEPTB;Nz63PFM{OyEQvF2= Ml\GV2FPT0WU
SKG-IIIa NWfa[I45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGyXnFKSzVyPUeuPFE5QTJizszN MWLTRW5ITVJ?
HCE-T M2\2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTdwOEe3PFMh|ryP M4H2NHNCVkeHUh?=
Ca-Ski MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;McGs4UUN3ME23Mlk6Ozh|IN88US=> M2[2SnNCVkeHUh?=
COLO-684 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRThwMEG4NVgh|ryP MoLXV2FPT0WU
KYSE-70 NYDrcIpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX20NZJOUUN3ME24MlA4PzJ7IN88US=> MoTOV2FPT0WU
TI-73 NXvtd|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3Ec|NbUUN3ME24MlI2QDVzIN88US=> MoXQV2FPT0WU
BT-20 M3[3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuyUZZKSzVyPUiuNlYxPTJizszN NUjlcmhiW0GQR1XS
MHH-ES-1 NYrrU4k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRThwNUG4N|Qh|ryP NXnXdodDW0GQR1XS
TE-12 M1PXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\3TWM2OD16LkW5PVMyKM7:TR?= NXjaOodwW0GQR1XS
YH-13 NEG0eW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXVXmdCUUN3ME24MlYyODB6IN88US=> NHTOXIlUSU6JRWK=
SF126 M1\6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRThwOEO4OlUh|ryP MoHVV2FPT0WU
J82 NELY[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DDeWlEPTB;OD65NFA{QCEQvF2= MXHTRW5ITVJ?
RCC10RGB NV;5b|Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRThwOUm1OlEh|ryP MkSwV2FPT0WU
SK-UT-1 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSxfWJvUUN3ME25MlA1QTR3IN88US=> M3HsSHNCVkeHUh?=
LB2241-RCC NUnt[WFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDyNVJrUUN3ME25MlE6OTN5IN88US=> MkPDV2FPT0WU
LB996-RCC M{PscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;QTWM2OD17LkG5PFkh|ryP NF\De5BUSU6JRWK=
EPLC-272H MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnERYViUUN3ME25MlM4PjV5IN88US=> M4Prb3NCVkeHUh?=
CTV-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTlwNU[1N|Ih|ryP M4LOcnNCVkeHUh?=
HSC-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HGV2lEPTB;OT61O|U2KM7:TR?= M1rHenNCVkeHUh?=
SK-MEL-28 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjMfJhKSzVyPUmuOlE5QTNizszN MlfEV2FPT0WU
MMAC-SF M3zW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTLTWM2OD17Lk[4O|Uh|ryP MYPTRW5ITVJ?
CP50-MEL-B M{nFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTlwN{W3PFIh|ryP NFLsdFlUSU6JRWK=
HT-1080 NH:5bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrhTWM2OD17Lke3O|M6KM7:TR?= M{fCRnNCVkeHUh?=
HEC-1 NXHVcJRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnpTWM2OD1zMD6zN|UzKM7:TR?= M1XvXHNCVkeHUh?=
AGS NWWxeXJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S4VmlEPTB;MUCuN|c1KM7:TR?= NHjxXm5USU6JRWK=
GAMG M163PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFyLkWxOlIh|ryP M{PSeHNCVkeHUh?=
SW48 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nZcWlEPTB;MUCuOVE5QSEQvF2= MnjOV2FPT0WU
U031 NGnqN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrtS402UUN3ME2xNE42QTB6IN88US=> NELOfGFUSU6JRWK=
OVCAR-5 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HUe2lEPTB;MUCuOlQzQSEQvF2= MVfTRW5ITVJ?
SF295 NGDEW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jFNmlEPTB;MUCuOlcxPCEQvF2= M1XPNXNCVkeHUh?=
BHT-101 NWjJO257T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPo[HN4UUN3ME2xNE44OTd5IN88US=> MmnPV2FPT0WU
VMRC-RCZ MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFzLkOyNFEh|ryP NFO4Z3RUSU6JRWK=
ACHN MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvWTWM2OD1zMT60NlEyKM7:TR?= M4q4NnNCVkeHUh?=
NCI-H526 NVLuem9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFzLkWwOFMh|ryP MmexV2FPT0WU
MN-60 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn3TWM2OD1zMT61N|kh|ryP Mlr4V2FPT0WU
NCI-H2291 NUHOUJg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DqOGlEPTB;MUGuOVQ3PiEQvF2= MULTRW5ITVJ?
SCC-25 NWHCclJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zDfmlEPTB;MUGuO|U2PiEQvF2= NWnFSYhPW0GQR1XS
SK-MEL-2 NWXxSWRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFzLke2N|ch|ryP NFq3TI1USU6JRWK=
SN12C MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn0UYpKSzVyPUGxMlk{PTVizszN MWTTRW5ITVJ?
NCI-H69 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF{LkSyN|Qh|ryP MlX0V2FPT0WU
ME-180 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF{LkewOVQh|ryP MXjTRW5ITVJ?
MC-IXC NXO2dZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq2WGJKSzVyPUGyMlc2OThizszN MXrTRW5ITVJ?
NCI-H2347 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF{Lke2NVQh|ryP NGrDTlBUSU6JRWK=
M059J NUTWZ5dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXHTWM2OD1zMj63O|I4KM7:TR?= NVTkXZpIW0GQR1XS
A2058 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF{Lki2PFEh|ryP M336XHNCVkeHUh?=
VA-ES-BJ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XRV2lEPTB;MUKuPFc5PSEQvF2= NGnMT2pUSU6JRWK=
Ca9-22 M3LYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjMeYRKSzVyPUGyMlk1PTFizszN M1rVNXNCVkeHUh?=
KNS-42 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn32TWM2OD1zMj65PVg1KM7:TR?= NUOyVoZrW0GQR1XS
LoVo MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n3UGlEPTB;MUOuNlMyOyEQvF2= NHThOpFUSU6JRWK=
AM-38 M33BPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ey[2lEPTB;MUOuNlU3PiEQvF2= M3WwfHNCVkeHUh?=
NB5 NXvtR|V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfrTWM2OD1zMz6zO|UzKM7:TR?= NW\mcYFFW0GQR1XS
L-363 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjkWJdKSzVyPUGzMlQxOzNizszN NVzGXHc1W0GQR1XS
SK-MEL-30 NYntbIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\ifGNVUUN3ME2xOE4xPjR3IN88US=> NUD1WJJTW0GQR1XS
NCI-H1563 M32zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHaTWM2OD1zND62NFM6KM7:TR?= NYDsSYlZW0GQR1XS
NCI-H2228 NIHXb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrlWodoUUN3ME2xOE43ODd5IN88US=> MnPsV2FPT0WU
MFM-223 M{Dpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX6b2JKSzVyPUG1MlE5OTNizszN NIPFdFVUSU6JRWK=
LB831-BLC MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmzVXdkUUN3ME2xOU4zPzZ5IN88US=> MnfyV2FPT0WU
SW872 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj3[2hKSzVyPUG1MlMxQDZizszN M4fjWnNCVkeHUh?=
NCI-H522 NW\welBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jLcmlEPTB;MUWuN|MxPiEQvF2= NX:3TFJmW0GQR1XS
EW-1 M{\y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:zUZFKSzVyPUG1MlU1PjJizszN NIfRdmNUSU6JRWK=
HN NITEbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF3LkW5OFIh|ryP MkezV2FPT0WU
SW837 NYjTRW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fY[mlEPTB;MUWuO|g1PyEQvF2= MmLhV2FPT0WU
SCC-9 M1juW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF3LkixNVQh|ryP NWPDc3M{W0GQR1XS
MKN7 NGKwZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HCNGlEPTB;MUWuPVc{OiEQvF2= MUnTRW5ITVJ?
KYSE-410 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\DS|N2UUN3ME2xOk42QTFizszN MV;TRW5ITVJ?
SK-N-DZ NYD6RlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DmemlEPTB;MU[uOlEyPiEQvF2= MliwV2FPT0WU
COR-L105 M17WS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;6VWlEPTB;MU[uOlUzQCEQvF2= NIHrdHVUSU6JRWK=
LB2518-MEL MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ZfFhyUUN3ME2xOk45Ozh7IN88US=> MV3TRW5ITVJ?
OVCAR-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX71d4lCUUN3ME2xOk45QDZ{IN88US=> MVvTRW5ITVJ?
TK10 NHXaOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy0RplKSzVyPUG2Mlk1PzNizszN NHrTNplUSU6JRWK=
KNS-62 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXkWHpKSzVyPUG2Mlk4PzdizszN NF;lVmZUSU6JRWK=
RPMI-8866 M2PNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDGTWM2OD1zNz6xO|MzKM7:TR?= MVTTRW5ITVJ?
HuP-T4 M2DPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fqdmlEPTB;MUeuNlQ6PSEQvF2= M4jlTXNCVkeHUh?=
CGTH-W-1 M1;qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rNemlEPTB;MUeuOVIyQSEQvF2= NXThfYZlW0GQR1XS
T-24 M1XXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTUTWM2OD1zNz61N|Q4KM7:TR?= NV[2O3NVW0GQR1XS
HT-3 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF5LkW5NVQh|ryP NWfRe242W0GQR1XS
KS-1 M4PhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzrTWM2OD1zNz62O|Mh|ryP NE\BXWtUSU6JRWK=
NCI-H1792 M{\o[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nhOmlEPTB;MUeuO|k5KM7:TR?= Mnz1V2FPT0WU
ABC-1 NF;wc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF5LkixOFEh|ryP MojWV2FPT0WU
BPH-1 NYmyPIkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW3NIhWUUN3ME2xPE4yPjh3IN88US=> NXPhZZZyW0GQR1XS
A431 NXGye3dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF6LkSxNlch|ryP NXPyfWRDW0GQR1XS
T98G NGjjb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW1TWM2OD1zOD61NVU4KM7:TR?= NGG0eJZUSU6JRWK=
BHY MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF6Lki2PUDPxE1? M1;IV3NCVkeHUh?=
Capan-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojoTWM2OD1zOD65NFc5KM7:TR?= NWTke2o1W0GQR1XS
MDA-MB-175-VII NH3wNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XWTmlEPTB;MUiuPVIxQSEQvF2= NGrWNodUSU6JRWK=
CAL-27 NFjJfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PJSWlEPTB;MUmuNFQ5PyEQvF2= NGftTI9USU6JRWK=
AsPC-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXTUYFKSzVyPUG5Mlg3PTdizszN M4HiOnNCVkeHUh?=
KU812 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfmNHdrUUN3ME2xPU46PTd|IN88US=> MlnBV2FPT0WU
NCI-H441 NVLKWIZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTOfmpoUUN3ME2yNE4xODFizszN NWLBdZNUW0GQR1XS
Mewo NHfNVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i4eGlEPTB;MkCuNVI5QCEQvF2= MkPIV2FPT0WU
SK-MEL-24 NXvPdG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;GV4JKSzVyPUKwMlE1PzdizszN MU\TRW5ITVJ?
NCI-H727 NVnpVZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;zOI1KSzVyPUKwMlI4ODRizszN M{DyOnNCVkeHUh?=
EKVX Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPKTWM2OD1{MD62NFYh|ryP M{XpWXNCVkeHUh?=
RT-112 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jXcGlEPTB;MkCuOlEzOiEQvF2= MWTTRW5ITVJ?
CAMA-1 MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37E[WlEPTB;MkCuPVgxOyEQvF2= NXm0WG5tW0GQR1XS
SW900 M1W0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJzLkCxOFkh|ryP NHLMc5VUSU6JRWK=
NCI-H23 M3vnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDFe2lKUUN3ME2yNU4yOjd5IN88US=> NGnoWGlUSU6JRWK=
SK-PN-DW MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[4WGZqUUN3ME2yNU4yPjR7IN88US=> NWjjN5hXW0GQR1XS
BB30-HNC NIrlTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYriW3BYUUN3ME2yNU4zPzR3IN88US=> NIq1NnlUSU6JRWK=
VM-CUB-1 NV6zbpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuxRZJ[UUN3ME2yNU4{PTN4IN88US=> NFXnbJlUSU6JRWK=
IST-MEL1 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPIZmFKSzVyPUKxMlM3QTJizszN Mm\uV2FPT0WU
CTB-1 NHzhXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfNNYNKSzVyPUKxMlQ4PTVizszN NILLOllUSU6JRWK=
LCLC-103H NWCyc2htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ{LkG1PFIh|ryP M1f4NnNCVkeHUh?=
PANC-03-27 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ{LkWxOlkh|ryP M3zDVHNCVkeHUh?=
HTC-C3 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ{LkW1OVUh|ryP M3y5S3NCVkeHUh?=
TE-8 NWPCe4Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ|LkK1OlUh|ryP MX7TRW5ITVJ?
NCI-H292 NVvl[YlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\PRXFpUUN3ME2yOU4{PTN4IN88US=> M2LVVHNCVkeHUh?=
COLO-680N MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H2NWlEPTB;MkWuOlMzQSEQvF2= M1:0bHNCVkeHUh?=
KYSE-520 M1LGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ3Lk[0OEDPxE1? M3TRfXNCVkeHUh?=
NB10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\zc5FpUUN3ME2yOk4{OTF5IN88US=> Mo\xV2FPT0WU
NCI-H661 M33FfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXo[XJKSzVyPUK2MlQ4OTNizszN MkTnV2FPT0WU
GMS-10 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rtfGlEPTB;Mk[uPFY{QCEQvF2= MY\TRW5ITVJ?
NCI-H2122 NVHMPZRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT4TWM2OD1{Nj65PVk5KM7:TR?= M2njc3NCVkeHUh?=
OVCAR-8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj6[oFjUUN3ME2yO{4xPjN6IN88US=> M3vrXHNCVkeHUh?=
DJM-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliwTWM2OD1{Nz6xOFU1KM7:TR?= NHTlR|BUSU6JRWK=
UACC-893 NV7ON5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ5Lkm4O|gh|ryP NGTObJVUSU6JRWK=
C8166 NXrobm9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;ITWM2OD1{OD62PVM5KM7:TR?= NU\HWYx6W0GQR1XS
NCI-H1693 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;oPGlEPTB;MkiuOlk4PSEQvF2= M1;lU3NCVkeHUh?=
TYK-nu NXyzc3B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTQdW5KSzVyPUOwMlA{PDVizszN NHixbWtUSU6JRWK=
SW1710 NV\1e3AxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNyLkGyOkDPxE1? Ml;nV2FPT0WU
A375 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PsVWlEPTB;M{CuN|I1OyEQvF2= MkjJV2FPT0WU
HMV-II MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfubIFKSzVyPUOxMlM2QTJizszN Ml;mV2FPT0WU
NCI-H2087 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTyTWM2OD1|MT62N|UzKM7:TR?= M13hW3NCVkeHUh?=
CAL-54 NHS5TW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;WcmlEPTB;M{GuO|I1OSEQvF2= MofYV2FPT0WU
HCC70 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN{LkGzPFch|ryP NWe0[WZjW0GQR1XS
ES1 M{O0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN{LkOwOlIh|ryP NIn0TopUSU6JRWK=
NCI-H1355 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\5TWM2OD1|Mz6yNFQh|ryP NXXPNmhsW0GQR1XS
CFPAC-1 NYPEbZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmxTWM2OD1|Mz6yN|MzKM7:TR?= M3vJTHNCVkeHUh?=
MKN28 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN|LkO4NFkh|ryP NUDVOmNuW0GQR1XS
HDLM-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN|Lk[5N|Eh|ryP M{fEW3NCVkeHUh?=
PANC-10-05 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrWTWM2OD1|ND6xNFE1KM7:TR?= MWrTRW5ITVJ?
SAS M1PsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjyV|lZUUN3ME2zOE41PTZ3IN88US=> NXLrTY13W0GQR1XS
HCC1395 NH\lS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\TTWM2OD1|ND63NVg3KM7:TR?= NUHtSFVJW0GQR1XS
8305C NGTUO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnGTWM2OD1|NT64OFE2KM7:TR?= MXTTRW5ITVJ?
KM12 NWTqUYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37Gc2lEPTB;M{[uO|U1PyEQvF2= MmfnV2FPT0WU
SW1116 NVHSfFVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zFc2lEPTB;M{euOVk6OiEQvF2= M17YeXNCVkeHUh?=
SK-MEL-1 MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPrPY51UUN3ME2zPE4{Ozh7IN88US=> MVTTRW5ITVJ?
HCC2218 M2nQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN6Lk[1NVkh|ryP NFzpWGJUSU6JRWK=
T84 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fOSmlEPTB;M{iuO|QxQSEQvF2= NYTiPJBUW0GQR1XS
ETK-1 NFTBZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfZenVKSzVyPUO5MlAzOiEQvF2= MnTLV2FPT0WU
COLO-800 NYP3fI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTN7LkO4Olgh|ryP NH3FdJpUSU6JRWK=
CAL-12T M13OXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ofVh6UUN3ME2zPU42OjhzIN88US=> NEnkeGJUSU6JRWK=
ACN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K3WWlEPTB;NECuOFkyOSEQvF2= NFnSXYtUSU6JRWK=
SJSA-1 M4DhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXkTWM2OD12MT6xOVk3KM7:TR?= MkXlV2FPT0WU
PSN1 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXexSXpiUUN3ME20NU4yPzR7IN88US=> NGTwO|hUSU6JRWK=
D-566MG M1q3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\VToR3UUN3ME20NU4zODh4IN88US=> M33kRXNCVkeHUh?=
EGI-1 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyzNY5KSzVyPUSyMlQzQCEQvF2= M{e3U3NCVkeHUh?=
A204 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXXWnhsUUN3ME20Nk43Ozh6IN88US=> MWTTRW5ITVJ?
Saos-2 M{i0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR{LkizOlkh|ryP MojRV2FPT0WU
SNU-C2B MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrBZo9HUUN3ME20N{43QDd6IN88US=> M3vjfXNCVkeHUh?=
HLE MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ftO2lEPTB;NESuNFg2PiEQvF2= M1f2NnNCVkeHUh?=
SW1463 NYLlOohpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDVbXU5UUN3ME20OE46QTdzIN88US=> MoXPV2FPT0WU
DSH1 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj4TWM2OD12NT6wNFM{KM7:TR?= NGPab|hUSU6JRWK=
MCF7 NIf6N4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvN[5A6UUN3ME20OU42ODVzIN88US=> NVfwdodyW0GQR1XS
K5 NHHVR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi4TJI4UUN3ME20OU46PDB3IN88US=> MVLTRW5ITVJ?
NCI-H358 NILve2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTR5LkKxOUDPxE1? NX;DN40yW0GQR1XS
NCI-H2030 M{XVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTyTWM2OD12Nz6yN|c1KM7:TR?= NEPJNmFUSU6JRWK=
SW948 NV3GW3J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vHeWlEPTB;NEeuOFY1KM7:TR?= NIjzOXhUSU6JRWK=
BALL-1 NILo[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e0bWlEPTB;NEeuOlE3QCEQvF2= NW\tTpZwW0GQR1XS
TE-9 NXjRWXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR5Lkm1PFEh|ryP M4C3UnNCVkeHUh?=
SK-N-FI MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXhZ2hHUUN3ME20PE4xOzV6IN88US=> NWO5TYdkW0GQR1XS
KALS-1 NXy4eZNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXyTWM2OD12OD6xNlg6KM7:TR?= Mmm5V2FPT0WU
HO-1-N-1 NGW2RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPOTWM2OD12OD63OFQ2KM7:TR?= NV;MNog2W0GQR1XS
NCI-H2452 M3;HWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXjTWM2OD12OT6xNVUzKM7:TR?= MXzTRW5ITVJ?
OC-314 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDp[FZKSzVyPUS5MlY5OzRizszN MYHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID